Overview
United BioSource Corporation (UBC) announced the acquisition of BioCor LLC, a Yardley, Pennsylvania-based provider of clinical data services to the pharmaceutical and biotechnology industries.
BioCor delivers dedicated clinical data services and medical writing capabilities to support the regulatory approval process for new drugs, from initial filing of an investigational new drug (IND) application to the final submission of a new drug application (NDA).
UBC provides science-based solutions to support the development and commercialization of pharmaceuticals, biotechnology, and medical devices.
Significance
BioCor biostatisticians and medical writers will join UBC’s growing roster of scientific experts; about 50 percent of BioCor’s professional staff hold a doctorate in a scientific discipline.
“As more of these companies take their products through NDA submission and commercialization, they depend on outsourcing partners to help integrate, interpret, and submit their data as rapidly and as efficiently as possible. With the addition of BioCor’s team, UBC now offers the industry’s strongest combination of scientific expertise and high-quality service in a highly specialized field,” said Ethan Leder, UBC’s CEO.
The addition of BioCor is the latest in a series of acquisitions announced since UBC raised $153 million in equity capital from a syndicate of leading private equity firms.
Crosstree’s Role
Crosstree Capital served as exclusive financial advisor to BioCor.
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
